tbuckley/cabot-search huggingface dataset:
51626 Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data From a Phase 2 Upadacitinib Study in Adults With Nonsegmental Vitiligo
Authors: Khaled Ezzedine, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, Iltefat Hamzavi
Journal: Journal of the American Academy of Dermatology (2024)
54695 Access to specialist care and perceived care quality among melanoma and non-melanoma skin cancer patients: A Medical Expenditure Panel Survey Analysis
Authors: Celine M. Schreidah, Lauren M. Fahmy, Caroline Chen, Emily R. Gordon, Oluwaseyi Adeuyan, Brigit A. Lapolla, Joshua A. Kent, Larisa J. Geskin
Journal: Journal of the American Academy of Dermatology (2024)
51486 Management of Cutaneous Rosai-Dorfman Disease: A Retrospective Cohort Study at a Single Academic Cancer Center
Authors: Stephanie Choi, Christopher J. Fay, Iulianna C. Taritsa, Blair S. Allais, Debjani Sahni, Eric D. Jacobsen, Nicole R. LeBoeuf
Journal: Journal of the American Academy of Dermatology (2024)
50830 Dermatologists’ perspectives on the usage of AI-based large language models in practice- an exploratory survey
Authors: Haiwen Gui, Daniel Schlessinger, Jason Weed, Jenna Lester, Shannon Wongvibulsin, Dom Mitchell, Justin Ko, Veronica Rotemberg, Ivy Lee, Roxana Daneshjou
Journal: Journal of the American Academy of Dermatology (2024)
52766 Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: Results at Months 6 and 12 from the PSoHO study in real-world settings
Authors: Andrew Blauvelt, Charles Lynde, Julia-Tatjana Maul, Claudia Bernabé del Río, Jens Gammeltoft Gerwien, Christopher Schuster, Anastasia Lampropoulou, Wei Gang Zhang, Georgia Martimianaki, Felix Lauffer
Journal: Journal of the American Academy of Dermatology (2024)
54285 Evaluating the Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Platysma Prominence: Results from a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Authors: Sachin M. Shridharani, Megan Couvillion, Edward Lain, Patricia Ogilvie, Tatjana Pavicic, Grace S. Park, Warren Tong, Elisabeth Lee, René Hopfinger
Journal: Journal of the American Academy of Dermatology (2024)
54029 Pooled Patient-Reported Outcomes from the Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
Authors: Natasha A. Mesinkovska, Brett King, Arash Mostaghimi, Colleen Hamilton, James Cassella
Journal: Journal of the American Academy of Dermatology (2024)
54033 Baricitinib in Cutaneous Lichen Planus- Phase 2 trial results with dose escalation.
Authors: Angelina Hwang, Jacob Kechter, Nan Zhang, Alysia Hughes, Shams Nassir, Emily Branch, Samantha Zunich, Mark Pittelkow, Johann Gudjonsson, Aaron Mangold
Journal: Journal of the American Academy of Dermatology (2024)
50812 Infant Skin Microbiome is Associated with Decreased Risk of Atopic Dermatitis and Affected by Early Use of an Emollient
Authors: Richard A. Insel, Jonathan O’B. Hourihane, Albert Palleja, Janne Marie Moll, Nikolaj Sørensen, Alan D. Irvine, Georgios Stamatas
Journal: Journal of the American Academy of Dermatology (2024)
54091 Biologic efficacy and reasons for discontinuation in a tertiary referral hidradenitis suppurativa clinic
Authors: Albert Young, Kathy Lu, Andrea Dai, Dheeraj Kagithala, Eglal Samir, Mark Gregory, Madison Romanski, Peter Dimitrion, Iltefat Hamzavi, Qing-Sheng Mi
Journal: Journal of the American Academy of Dermatology (2024)
51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Authors: Maryanne Makredes Senna, Brett King, Natasha A. Mesinkovska, Arash Mostaghimi, Colleen Hamilton, James Cassella
Journal: Journal of the American Academy of Dermatology (2024)
54468 Racial and socioeconomic inequities in atopic dermatitis care: A study of price and pharmacy deserts for recommended skincare products
Authors: Karina Grullon, Stephanie Cardenas, Natalia Khosla, Michelle Verghese, Karina Grullon, Dima Halabi, Adena Rosenblatt
Journal: Journal of the American Academy of Dermatology (2024)
54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Authors: Richard G. Langley, David Fiorentino, Jerry Bagel, Kimberly Parnell Lafferty, Elizabeth Skobelev, Wayne Langholff, Mark Lebwohl, Vincent Ho, Bruce Strober
Journal: Journal of the American Academy of Dermatology (2024)
53106 Primary cutaneous melanoma patients stratified by the Merlin assay (CP-GEP): risk of nodal metastasis and long-term survival outcome in a U.S. cohort
Authors: Wesley Yu, Sheena Hill, Kord Honda, Bethany R. Rohr, Renske Wever, Felicia Tjien-Fooh, Jvalini Dwarkasing
Journal: Journal of the American Academy of Dermatology (2024)
49147 Comparing the Quality of ChatGPT- and Physician-Generated Responses to Patients' Dermatologic Questions in the Electronic Medical Record
Authors: Kelly Reynolds, Daniel Nadelman, Joseph Durgin, Stephen Ansah-Addo, Daniel Cole, Rachel Fayne, Jane Harrell, Madison Ratycz, Mason Runge, Amanda Shepard-Hayes, Trilokraj Tejasvi
Journal: Journal of the American Academy of Dermatology (2024)
54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics From the LIMMitless Trial
Authors: Bruce Strober, Tianshuang Wu, Huzefa Photowala, Michael M. Chen, Hervé Bachelez
Journal: Journal of the American Academy of Dermatology (2024)
54728 Prevalence of post-inflammatory hyperpigmentation, impact on quality of life and social stigmatization: results of the first large international survey
Authors: Delphine Kerob Kerob, Thierry Passeron, Andrew Alexis, Brigitte Dreno, Liu Wei, Akimichi Akimichi Morita, Chee Leok, Hen Young Kang, Fatimata Ly, Sergio Schalka
Journal: Journal of the American Academy of Dermatology (2024)
53188 A Global Analysis of Cutaneous Lymphomatoid Reactions after COVID-19 Vaccination
Authors: Emily R. Gordon, Bradley D. Kwinta, Celine M. Schreidah, Oluwaseyi Adeuyan, Lauren M. Fahmy, Dawn Queen, Megan H. Trager, Cynthia M. Magro, Larisa J. Geskin
Journal: Journal of the American Academy of Dermatology (2024)
52668 Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3-year results from BE BRIGHT, a multicenter, open-label, phase 3 study
Authors: Yukari Okubo, Yayoi Tada, Hidetoshi Takahashi, Masatoshi Abe, Keiichi Yamanaka, Nicola Tilt, Nancy Cross, Delphine Deherder, Mizuho Matano, Hidemi Nakagawa
Journal: Journal of the American Academy of Dermatology (2024)
52755 An association of vitamin B3, vitamin C and AHA in a topical serum is as beneficial as hydroquinone 4% and better tolerated in subjects with melasma
Authors: Juliane Rocio, Mukta Sachdev, Claire Deloche-Bensaim, Stéphanie Leclerc-Mercier, Camila Valpaços, Alessandro Nascimento, Priscila Correia, Beatriz Sant'Anna, Thierry Passeron
Journal: Journal of the American Academy of Dermatology (2024)
51784 Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
Authors: Saakshi Khattri, Álvaro González-Cantero, Burhan Engin, Sunil Dogra, Christopher Schuster, Naoto Tsujimoto, Anastasia Lampropoulou, Aya Alsharafi, Bruce Konicek, Felix Lauffer
Journal: Journal of the American Academy of Dermatology (2024)
52880 Guselkumab improves sexual health in patients with moderate-to-severe psoriasis, including patients across different age and weight groups: Results from the real-life G-EPOSS study until Week 76.
Authors: Sascha Gerdes, Sebastian Zimmer, Andreas Schwinn, Rolf Ostendorf, Simmy Jacobsen, Judita Makuc, Nina Trenkler, Juliane Behrens, Sarah Tabori, Dariusch Mortazawi
Journal: Journal of the American Academy of Dermatology (2024)
53083 Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA, when used for combination treatment of glabellar and lateral canthal lines
Authors: Joel Schlessinger, John Joseph, Ava Shamban, Z. Paul Lorenc, Robert Weiss, Hunt Valley, Vince Bertucci, Leslie Baumann, Mark S. Nestor, Heidi B. Prather, Derek Jones, Rebecca Kazin
Journal: Journal of the American Academy of Dermatology (2024)
51791 Guselkumab improves psoriatic skin and HRQoL outcomes across BMI subgroups, including patients with involvement of hard-to-treat areas: results from the real-world PERSIST study
Authors: Sascha Gerdes, Matthias Hoffmann, Dariusch Mortazawi, Khusru Asadullah, Simmy Jacobsen, Julia Sprenger-Perera, Alexander Egeberg
Journal: Journal of the American Academy of Dermatology (2024)
54494 A systematic review and meta-analysis exploring the risk of infections with janus kinase inhibitor treatment for plaque psoriasis
Authors: Muskaan Sachdeva, Nawar Tarafdar, Natnaiel Dubale, Iryna Savinova, Yuliya Lytvyn, Khalad Maliyar, Jorge R. Georgakopoulos, Asfandyar Mufti, Jensen Yeung
Journal: Journal of the American Academy of Dermatology (2024)
52584 Efficacy of Fluorouracil as Adjuvant Therapy in Treating Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery: A Multi-Year Single Institution Retrospective Study
Authors: Madeeha Drissi, Zaryab Alam, Hamza Malick, Chad Housewright
Journal: Journal of the American Academy of Dermatology (2024)
52715 Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the Phase 3 DELTA-1 and -2 trials
Authors: Robert Bissonnette, Margitta Wom, Richard B. Warren, Tove Agner, Melinda Gooderham, Marie Louise Schuttelaar, Keith Baranowski, Ursula Plohberger, Laura Sørensen, Sibylle Schliemann
Journal: Journal of the American Academy of Dermatology (2024)
54183 Intraleukin 17, hidradenitis suppurativa and response to adalimumab therapy
Authors: Daniel Vírseda-González, María Córdoba-García-Rayo, Luis Jiménez-Briones, Noelia Medrano-Martínez, Belén Rodríguez-Sánchez, Jorge Martín-Nieto-González, Rebeca Kennedy-Batalla, Cristina Ciudad-Blanco
Journal: Journal of the American Academy of Dermatology (2024)
50670 Exploring the Valuable Role of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Comprehensive Evaluation and Diagnostic Assessment of Hidradenitis Suppurativa
Authors: Sahithi Talasila, Eric Teichner, Robert Subtirelu, David Xiang, Cyrus Ayubcha, Thomas Werner, Abass Alavi
Journal: Journal of the American Academy of Dermatology (2024)
51687 Safety, Tolerability, and Efficacy of Diphencyprone for Cutaneous Neurofibromas in Adult Patients with Neurofibromatosis Type 1
Authors: Jeremy Orloff, Dina Poplauksy, Jade N. Young, Brandon Block, Ryan Rivera-Oyola, Patricia Cabral, Vicky K. Wong, Giselle Singer, Yeriel D. Estrada, Rebecca M. Brown, Nicholas Gulati
Journal: Journal of the American Academy of Dermatology (2024)
51101 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline static Physician Global Assessment (sPGA) in two phase 3 trials
Authors: Jeffrey M. Sobell, Boni Elewski, Seong Jun Seo, Subhashis Banerjee, Eugene Balagula, Thomas Scharnitz, Kim Hoyt, Paul Yamauchi, Miriam Bettencourt, Michael C. Cameron, Mark Lebwohl
Journal: Journal of the American Academy of Dermatology (2024)
51076 Interim Analyses from the BEACON Trial: A Phase 2, Randomized, Open-label Trial of Bitopertin in Erythropoietic Protoporphyria
Authors: Gayle Ross, Peter Stewart, George Mensing, Melanie Chin, Haley Howell, Heidi Mangus, Will Savage
Journal: Journal of the American Academy of Dermatology (2024)
53889 Impact of DFD-29, a Low-Dose Oral Minocycline, on Skin, Gastrointestinal Tract, and Vaginal Microflora in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
Authors: Srinivas Sidgiddi, Neal Bhatia, Srinivas Sidgiddi
Journal: Journal of the American Academy of Dermatology (2024)
51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data
Authors: Andrew Blauvelt, Howard Sofen, Jo Lambert, Joseph F. Merola, Mark Lebwohl, Kim Hoyt, Renata M. Kisa, Subhashis Banerjee, Thomas Scharnitz, Jeffrey J. Crowley
Journal: Journal of the American Academy of Dermatology (2024)
53683 Remibrutinib provides sustained improvement in itch severity in patients with chronic spontaneous urticaria: Phase 2b open-label extension study
Authors: Robert Snyder, Alexander Greiner, Vipul Jain, Ana Maria Giménez-Arnau, Karine Lheritier, Pauline Walsh, Ivan Nikolaev, Sibylle Haemmerle, Lee Clore
Journal: Journal of the American Academy of Dermatology (2024)
53307 Immune Checkpoint Inhibitor Antibody Type Influences on the Development of Cutaneous Immune-Related Adverse Events and Rash Morphology
Authors: Sara Khattab, Katie Roster, Ahmad Rajeh, Nga Nguyen, Kimberly Tang, Shijia Zhang, Hannah Rashdan, Guihong Wan, Bonnie Leung, Yevgeniy Semenov
Journal: Journal of the American Academy of Dermatology (2024)
49567 Investigating the Benefit of Visual Education on Patients’ Expectations of Stages of Wound Healing
Authors: Shirley Lin, Aaron Bao, Emanuelle Rizk, Chi Trinh, Calvin O'Donnell, Luke Zhao, Rachel De Armas, Xindi Chen, Elise Ng, Jeffrey Scott, Kristin Bibee
Journal: Journal of the American Academy of Dermatology (2024)
51558 Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Authors: Joseph F. Merola, Alice B. Gottlieb, Barbara Ink, Rajan Bajracharya, Jérémy Lambert, Jason Coarse, Ennio G. Favalli
Journal: Journal of the American Academy of Dermatology (2024)
54112 Improvements in Psoriasis Area and Severity Index and in Percent Body Surface Area of Psoriasis With JNJ-77242113: Treat-to-Target Analyses in the FRONTIER 1 Study
Authors: Kim A. Papp, Laura Ferris, Andreas Pinter, Phoebe Rich, Ronald Vender, Andrew Pink, Megan Miller, Yaung-Kaung Shen, Cynthia DeKlotz, Ya-Wen Yang, Robert Bissonnette
Journal: Journal of the American Academy of Dermatology (2024)
52164 Atopic Rhapsody: Eczema and Inborn Errors of Immunity
Authors: Priscilla Lizeth Cruz-Hernández, María de la Luz Orozco-Covarrubias, Juan Carlos Bustamante-Ogando, Marco Antonio Yamazaki-Nakashimada, María del Mar Sáez-de-Ocariz
Journal: Journal of the American Academy of Dermatology (2024)
52661 Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open label extension phase 3 trial
Authors: Andrew Blauvelt, Peter Foley, Richard G. Langley, Curdin Conrad, David Rosmarin, Ricardo Romiti, Maggie Wang, Balint Szilagyi, Bengt Hoepken, Richard B. Warren
Journal: Journal of the American Academy of Dermatology (2024)
51219 Lebrikizumab Monotherapy Maintained Improvement of Itch and Sleep-Loss Due to Itch After Two Years in Patients with Moderate-to-Severe Atopic Dermatitis
Authors: Gil Yosipovitch, Peter Lio, David Rosmarin, Marta Casillas, Fan Emily Yang, Chaoran Hu, Evangeline Pierce, Franz J. Legat, Jose-Manuel Carrascosa, Sonja Ständer
Journal: Journal of the American Academy of Dermatology (2024)

Introduction: Atopic dermatitis (AD) is a chronic disease with itch and sleep-loss due to itch as key symptoms, which requires long-term treatment and sustained response. We describe the impact of lebrikizumab on itch and sleep-loss due to itch at 104-weeks in a long-term extension study, ADjoin (NCT04392154).
53054 PD-1 Inhibitor Use for Skin Malignancies in Patients with Solid Organ and Bone Marrow Transplants: Graft Rejection, Treatment Responses, and Survival
Authors: Lily Parker, Kate Beekman, Meredith Thomley, Lilia Correa, Rahul Mhaskar
Journal: Journal of the American Academy of Dermatology (2024)
53261 Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among cutaneous melanoma patients in the Veterans Affairs Health System
Authors: Daniel Kim, Susan Swetter, Linden Huhmann, Matthew Dizon, Jacqueline Ferguson, Thomas Osborne, Allyson Spence, Amina Ziad, Nathanael Fillmore, Rebecca Hartman
Journal: Journal of the American Academy of Dermatology (2024)
51067 Beyond Race-Ethnicity: Fitzpatrick Skin Type Analysis Highlights Unmet Needs and Differing Treatment Patterns in Psoriasis among the Conventional Systemics Cohort of British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Authors: Kave Shams, Kathy Tran, Jennifer Montgomery, Meda Sandu, Methodios Typou, Isobel Piper, Myriam Cordey Missoup
Journal: Journal of the American Academy of Dermatology (2024)
50555 Equitable Healing: Are Phototherapy Recommendations Equitable for Cutaneous T-Cell Lymphoma Patients of Diverse Skin Types?
Authors: Caroline Chen, Oluwaseyi Adeuyan, Emily R. Gordon, Celine M. Schreidah, Lauren M. Fahmy, Brigit A. Lapolla, Larisa J. Geskin
Journal: Journal of the American Academy of Dermatology (2024)
51638 A Population Based Study of Mental Health and Socioeconomic Status in Psoriasis Patients with Skin of Color
Authors: Rebecca K. Yamamoto, Hannah C. Tolson, Sara N. Bilimoria, Kaviyon Sadrolashrafi, Robin Kikuchi, Danielle Yee, Audrey Hao, April W. Armstrong
Journal: Journal of the American Academy of Dermatology (2024)
54160 Neuropathic pruritus treated with bupivacaine injections: A case series
Authors: Alexander Kollhoff, Elena Wei, Anusha Kambala, Hannah Cornman, Sriya Reddy, Jaya Manjunath, Emily Ma, Brenda Umenita Imo, Shawn Kwatra
Journal: Journal of the American Academy of Dermatology (2024)
52685 Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
Authors: Diamant Thaçi, Luis Puig, Joseph F. Merola, Denis Jullien, Antonio Costanzo, Maggie Wang, Delphine Deherder, José M. López Pinto, Mark Lebwohl
Journal: Journal of the American Academy of Dermatology (2024)
52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
Authors: Arash Mostaghimi, Matthias Augustin, Kazutoshi Harada, Maryanne Senna, Yves Dutronc, Guanglei Yu, Susan Ball, Mwangi Murage, Jill Kolodsick, Brett King
Journal: Journal of the American Academy of Dermatology (2024)
51342 Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the Effisayil 2 and Effisayil ON trials
Authors: Diamant Thaçi, Akimichi Morita, Bruce Strober, Tiago Torres, Andreas Pinter, Angelo V. Marzano, James G. Krueger, Ming Tang, Patrick Hofmann, Christian Thoma, Mark G. Lebwohl
Journal: Journal of the American Academy of Dermatology (2024)
51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials
Authors: Linda Stein Gold, Subhashis Banerjee, Matthew J. Colombo, Renata M. Kisa, Victoria Berger, Kim Hoyt, Jennifer Soung, Tiago Torres, Neal Bhatia, Brad P. Glick, Mark D. Kaufmann
Journal: Journal of the American Academy of Dermatology (2024)
51826 PRO-C22 - A Novel Serological Biomarker of Tissue Damage is Associated with Disease Severity, Disease Activity, and Systemic Inflammation in Patients with Hidradenitis Suppurativa
Authors: Signe Holm Nielsen, Helena Port, Matej Andelic, Valdemar Wendelboe Nielsen, Nikolaj Holgersen, Jacob P. Thyssen, Morten Karsdal, Alexander Egeberg, Hans Christian Ring, Anne-Christine Bay-Jensen
Journal: Journal of the American Academy of Dermatology (2024)
54218 Achievement of high NPF treatment targets after 52 weeks in psoriasis patients switching to risankizumab after suboptimal response to secukinumab or ixekizumab
Authors: Richard B. Warren, Lev Pavlovksy, Antonio Costanzo, Neil Korman, Simone Rubant, Nadia Ibrahim, Yanbing Zheng, Vassilis Stakias, Diamant Thaçi
Journal: Journal of the American Academy of Dermatology (2024)
54214 Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis in Children Aged 2–&lt;12 Years by Previous Medication History: Subgroup Analysis From the Randomized, Phase 3 TRuE-AD3 Study
Authors: Lawrence F. Eichenfield, Weily Soong, Linda F. Stein Gold, Eric L. Simpson, Kristen E. Holland, Kanwaljit K. Brar, Lara Wine Lee, Howard Kallender, Daniel Sturm, Qian Li, Andrea L. Zaenglen
Journal: Journal of the American Academy of Dermatology (2024)
51240 R209, A Skin Penetrant IRAK1 and IRAK4 Inhibitor for Topical Indications
Authors: Simon Shaw, Hui Li, Meagan Chan, Yan Chen, Matt Duan, Thilo Heckrodt, Vadim Markovtsov, Chrystelle Lamagna, Vanessa Taylor, Esteban Masuda
Journal: Journal of the American Academy of Dermatology (2024)
50378 Clinical efficacy of TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, is associated with modulation of disease and TYK2 pathway biomarkers in patients with moderate-to-severe psoriasis
Authors: James G. Krueger, Sandra Garcet, Jie Cheng, Sachin Kumar, Jessamyn Blau, Yiwei Zhao, Wenwen Zhang, Vinayagam Arunachalam, Graham A. Heap, Paresh Thakker, Amit Choudhury
Journal: Journal of the American Academy of Dermatology (2024)
52030 Strategies for Improvement of the Virginia Dermatology Trainee Advocacy Day Conference
Authors: Ashley Jahed, Cosette Lim, Sanjoli Agarwal, Olivia Silveri, Kayla Tran, Hannah Harrelson, Darya Mirebrahimi, Elizabeth Rosenbaum, Madeline Coleman, Glynn Reno, Iain Encarnacion
Journal: Journal of the American Academy of Dermatology (2024)
52745 Decreased KLK5/PAR2 expression in epidermis keratinocytes in vitiligo contributed to the recruitment of cytotoxic CD8+ T cells via activation of Jak1/STAT1/CXCL 10 and impaired antioxidant capability via inhibition of Nrf2 signaling simultaneously
Authors: Mao Lin, Fujin Yang, Deming Liu
Journal: Journal of the American Academy of Dermatology (2024)
54020 Potent and selective TYK2 degraders, devoid of JAK activity, potently and completely suppress IL12/23 and IFN-a signaling pathways.
Authors: Anthony Slavin, Isaac Marx, Amy Wang, Fergus Byrne, Alex Wilkinson, Andreas Harsch, Kan-Nian Hu, Dirk Walther, Rahul Karnik, Nello Mainolfi, Matt Weiss
Journal: Journal of the American Academy of Dermatology (2024)
52844 Physician-Assessed Effectiveness and Safety in Adolescent and Adult Atopic Dermatitis Patients Treated with Dupilumab: Real-World Insights One Year into the GLOBOSTAD Multinational Prospective Observational Study
Authors: Silvia M. Ferrucci, Piergiacomo Calzavara-Pinton, Iva Karlova, Hilde Lapeere, Gregor Holzer, Mona Al-Ahmad, Chia-Yu Chu, Jiangming Wu, Marius Ardeleanu, Kwinten Bosman
Journal: Journal of the American Academy of Dermatology (2024)
50377 Factors associated with the initiation of a new systemic therapy among adults with atopic dermatitis: Data from the CorEvitas Atopic Dermatitis Registry
Authors: Eric Simpson, Alvin Li, Zach Dawson, Kaylee Ho, Linda Stein Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, Jonathan Silverberg
Journal: Journal of the American Academy of Dermatology (2024)
53946 Antihypertensive drugs and skin cancer, is there a relationship?
Authors: David Castillo-Molina, Jesus Daniel Fierro-Lozada, María Alejandra Contreras-Sánchez, Jennipher Andrea Blanco-Gómez, María Valentina Aponte-Aparicio, Sebastian Guerrero-López, Valeria Soto-Ariño, David E. Castillo-Saavedra, Meagan Ashley Norberta Klyn
Journal: Journal of the American Academy of Dermatology (2024)
51246 Apremilast Improves Clinical Outcomes and Pain in Patients With Oligoarticular Psoriatic Arthritis
Authors: Joseph Merola, Andreas Pinter, Kristina Callis Duffin, Jacob Aelion, Jyotsna Reddy, Rebecca Wang, Michele Brunori, Yuri Klyachkin, Laure Gossec, Philip Mease
Journal: Journal of the American Academy of Dermatology (2024)